Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902448 | 0.96 | CHRM4 (0.46) | SIGMAR1CHRM4NPFFR1NPFFR2NPC1L1 | |
| SCHEMBL14902444 | 0.90 | SIGMAR1 (0.51) | SIGMAR1CHRM4NPFFR1NPFFR2NPC1L1 | |
| SCHEMBL14902473 | 0.89 | SIGMAR1 (0.58) | SIGMAR1NPFFR1NPFFR2NPC1L1DRD2 | |
| SCHEMBL14902481 | 0.88 | SIGMAR1 (0.56) | SIGMAR1NPFFR1NPFFR2KCNH2DRD2 | |
| SCHEMBL14902468 | 0.87 | SIGMAR1 (0.59) | SIGMAR1NPFFR1NPFFR2NPC1L1KCNH2 | |
| SCHEMBL14902443 | 0.86 | SIGMAR1 (0.48) | SIGMAR1CHRM4NPFFR1NPFFR2NPC1L1 | |
| SCHEMBL14902523 | 0.83 | SIGMAR1 (0.48) | SIGMAR1NPFFR1NPFFR2NPC1L1DRD2 | |
| SCHEMBL14902447 | 0.82 | CHRM4 (0.46) | SIGMAR1CHRM4KCNH2NAMPTALDH1A1 | |
| SCHEMBL5811135 | 0.81 | OPRD1 (0.49) | — | |
| SCHEMBL14902452 | 0.79 | CHRM4 (0.47) | SIGMAR1CHRM4KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-9920035-B2 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9920035-B2 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| EP-2773633-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-20150336933-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336933-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20140228374-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228374-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8759349-B2 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759349-B2 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| WO-2013064450-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | SCNN1B, SCNN1A, TRPM5 | SIGMAR1 2217/4885CHRM4 1135/4885NPFFR1 3424/4885 |
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | SIGMAR1 2217/4885CHRM4 1135/4885NPFFR1 3424/4885 |
| US-20140228374-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | SCNN1B, SCNN1A, TRPM5 | SIGMAR1 2217/4885CHRM4 1135/4885NPFFR1 3424/4885 |
| US-20150336933-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | SCNN1B, SCNN1A, TRPM5 | SIGMAR1 2217/4885CHRM4 1135/4885NPFFR1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.